Oral absorption enhancement: Taking the next steps in therapeutic delivery

Therapeutic Delivery

Volumn 1, Issue 1, 2010, Pages 5-9

  Brayden, David J ^a   Maher, Sam ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREMOPHOR; ERYTHROPOIETIN; EXCIPIENT; FOOD ADDITIVE; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; MACROGOL;

DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; HUMAN; ILEITIS; INTERMETHOD COMPARISON; INTESTINE INJURY; INTESTINE TRANSIT TIME; LOZENGE; MOLECULAR WEIGHT; MOUTH MUCOSA; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PRODUCT SAFETY; REVIEW; RISK ASSESSMENT;

EID: 79955041496     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.14     Document Type: Review

References (25)

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420 (1995).
2. Russell-Jones GJ. Use of vitamin B12 conjugates to deliver protein drugs by the oral route. Crit. Rev. Ther. Drug Carrier Syst. 15, 557-586 (1998). (Pubitemid 29006580)
3. Brayden DJ, Jepson MA, Baird AW. Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov. Today 10, 1145-1157 (2005). (Pubitemid 41334666)
4. Higgins LM, Lambkin I, Donnelly G et al. In vivo phage display to identify M cell-targeting ligands. Pharm. Res. 21, 695-705 (2004). (Pubitemid 38457294)
5. Hauss DJ (Ed.). Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water Soluble Drugs. Informa Healthcare, Inc., NY, USA 1-339 (2007).
6. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 36, 43-48 (2008).
7. Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv. Drug Del. Rev. 59(15), 1482-1503 (2007). (Pubitemid 350122775)
8. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JK. Non-linear pharmacokinetics of paclitaxel in mice results from pharmaceutical vehicle Cremophor EL. Cancer Res. 56, 2112-2115 (1996). (Pubitemid 26119912)
9. Shen Q, Li W, Lin Y et al. Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in vitro and in situ absorption studies. J. Pharm. Pharmacol. 60, 1633-1641 (2008).
10. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 16, 1550-1556 (1999). (Pubitemid 29510551)
11. Cao X, Yu LX, Barbaciru C et al. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol. Pharm. 2, 329-340 (2005). (Pubitemid 41186409)
12. Maher S, Leonard TW, Jacobsen J, Brayden DJ. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61, 1427-1449 (2009).
13. Baluom M, Friedman M, Rubinstein A. Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. J. Control. Release 70, 139-1347 (2001).
14. Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97, 225-236 (2008).
15. Baldrick P. Pharmaceutical excipient development: the need for preclinical guidance. Reg. Tox. Pharmacol. 32, 210-218 (2000).
16. Steinberg M, Silverstein I. The use of unallowed excipients. Int. J. Toxicol. 22, 373-375 (2003). (Pubitemid 37377079)
17. Iyer H, Khedkar A, Verma M. Oral insulin: a review of current status. Diabetes Obes. Metab. 12, 179-185 (2010).
18. Blikslager AT, Moeser AJ, Gookin JL, Jones SL, Odle J. Restoration of barrier function in injured intestinal mucosa. Physiol. Rev. 87, 545-564 (2007). (Pubitemid 47084680)
19. Lanas A, Sopéa F. Non-steroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol. Clin. North Am. 38, 333-352 (2009).
20. Van Hoogdalem EJ, de Boer AG, Breimer DD. Pharmacokinetics of rectal administration. Part I: general considerations and clinical applications of centrally-acting drugs. Clin. Pharmacokinet. 21, 11-26 (1991).
21. Cox AB, Rawlinson LA, Baird AW, Bzik V, Brayden DJ. In vitro interactions between the oral absorption promoter, sodium caprate (C10) and S. typhimurium in rat intestinal ileal mucosae. Pharm. Res. 25, 114-122 (2008).
22. Makhlof A, Werle M, Tozuka Y, Takeuchi H. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J. Control. Release doi:10.1016/j.jconrel.2010.02.001 (2010) (Epub ahead of print).
23. Siekmeier R, Scheuch G. Inhaled insulin - does it become reality? J. Physiol. Pharmacol. 59(Suppl. 6), 81-113 (2008).
24. US Department of Health and Human Services, FDA. Guidance for industry nonclinical studies for the safety evaluation of pharmaceutical excipients www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/ guidances/ucm079250.pdf (Accessed 7 May 2010)
25. Bone Medical Technical Report www.bone-ltd.com/technical.htm (Accessed 6 May 2010)